Athena Countouriotis, M.D.
Athena Countouriotis, M.D., is the co-founder, President, and Chief Executive Officer of Avenzo Therapeutics. She previously led Turning Point Therapeutics as President and CEO from its IPO to eventual acquisition in 2022. With over 20 years of industry experience, Dr. Countouriotis has also led multiple development programs to approval in the U.S. and Europe. Dr. Countouriotis serves on the boards of Biomarin Inc., Iovance Biotherapeutics, Passage Bio, Recludix Pharma, and Leal Therapeutics, and previously was chairperson of Capstan Therapeutics.